ClinicalTrials.gg
CompletedNCT04493281Updated Jul 15, 2026Results posted

Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects

A Phase 1 interventional study of MT-1186 and MCI-186 in Healthy Adult Subjects, sponsored by Shionogi. Completed at 1 site in Japan. Open to participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by Shionogi · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Mar 2019, registered Jul 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
All
01

Study summary

To evaluate the single-dose bioequivalence of oral suspension and intravenous (IV) formulation of edaravone in the fasting state in healthy adult subjects

02

Conditions studied

  • Healthy Adult Subjects
03

In context

Lead sponsor

Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.

Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Healthy adult male or female volunteers
  • Japanese
  • Subjects aged between 20 and 45 years at the time of
  • Subjects who have thoroughly understood the contents of the study and voluntarily provided written informed consent to participate in the study

Exclusion Criteria: Additional screening criteria check may apply for qualification:

  • Subjects with a current or previous history of cardiac, hepatic, renal, gastrointestinal, respiratory, psychiatric/nervous, hematopoietic, or endocrine diseases, and those whom the investigator (or subinvestigator) deems unsuitable for the study
  • (BMI) of \<18.0 or >30.0, or body weight of \<50 kg (BMI formula: body weight [kg]/height [m]2, rounded to one decimal place)
  • Subjects who have undergone any surgery known to affect the gastrointestinal absorption of drugs
  • Female subjects who do not agree to use an effective method of from screening or 2 weeks before the start of product administration, whichever comes earlier, to 14 days after the completion (or discontinuation) of investigational product administration. Male subjects who do not agree to use an effective method of contraception from the start of investigational product administration to 14 days after the completion (or discontinuation) of investigational product administration
  • Subjects who have previously received edaravone
  • Subjects who have participated in another clinical study and received an investigational product within 12 weeks before providing informed consent
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    MT-1186

    Healthy subjects were administered a single dose of Edaravone oral suspension

    Drug: MT-1186

  • Active comparator
    MCI-186

    Healthy subjects were administered a single dose of Edaravone intravenous formulation

    Drug: MCI-186

Interventions

  • Oral suspension

    Also known as: Edaravone

  • Intravenous formulation

    Also known as: Edaravone

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration Versus Time Curve From Time Zero up to the Last Quantifiable Concentration Time-point (AUC0-t) of Unchanged Edaravone After Oral and Intravenous Administration

    Time frame: The date of dosing is defined as Day 1. PO: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; IV: Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Both groups: Day 2 at 24, 36 hrs; Day 3 at 48 hrs.

  2. Area Under the Plasma Concentration Versus Time Curve From Time Zero up to Infinity With Extrapolation of the Terminal Phase (AUC0-inf) of Unchanged Edaravone After Oral and Intravenous Administration

    Time frame: The date of dosing is defined as Day 1. PO: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; IV: Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Both groups: Day 2 at 24, 36 hrs; Day 3 at 48 hrs.

  3. Maximum Plasma Concentration (Cmax) of Unchanged Edaravone After Oral and Intravenous Administration

    Time frame: The date of dosing is defined as Day 1. PO: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; IV: Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Both groups: Day 2 at 24, 36 hrs; Day 3 at 48 hrs.

Secondary outcomes

  1. Time to Reach Maximum Plasma Concentration (Tmax)

    Time frame: The date of dosing is defined as Day 1. PO: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; IV: Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Both groups: Day 2 at 24, 36 hrs; Day 3 at 48 hrs.

  2. Area Under the Plasma Concentration Versus Time Curve From Time Zero up to 24 Hours (AUC0-24)

    Time frame: The date of dosing is defined as Day 1. PO: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; Day 2 at 24 hrs ; IV: Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75,2, 3, 4, 6, 8, 12 hrs; Day 2 at 24 hrs.

  3. Area Under the Plasma Concentration Versus Time Curve From Time Zero up to the Last Sampling Time-point (for All Time-points) (AUC0-all)

    Time frame: The date of dosing is defined as Day 1. PO: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; IV: Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Both groups: Day 2 at 24, 36 hrs; Day 3 at 48 hrs.

  4. Terminal Elimination Half-life (t1/2)

    Time frame: The date of dosing is defined as Day 1. PO: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; IV: Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Both groups: Day 2 at 24, 36 hrs; Day 3 at 48 hrs.

  5. Elimination Rate Constant From the Central Compartment (Kel)

    Time frame: The date of dosing is defined as Day 1. PO: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; IV: Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Both groups: Day 2 at 24, 36 hrs; Day 3 at 48 hrs.

  6. Mean Residence Time From Time Zero up to Infinity With Extrapolation of the Terminal Phase (MRT0-inf) of Unchanged Edaravone

    Time frame: The date of dosing is defined as Day 1. PO: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; IV: Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Both groups: Day 2 at 24, 36 hrs; Day 3 at 48 hrs.

  7. Total Clearance (CL) of Unchanged Edaravone After Intravenous Administration

    Time frame: The date of dosing is defined as Day 1. Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Day 2 at 24, 36 hrs; Day 3 at 48 hrs.

  8. Volume of Distribution During Terminal Phase (Vz) of Unchanged Edaravone After Intravenous Administration

    Time frame: The date of dosing is defined as Day 1. Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Day 2 at 24, 36 hrs; Day 3 at 48 hrs.

  9. Volume of Distribution at Steady State (Vss) of Unchanged Edaravone After Intravenous Administration

    Time frame: The date of dosing is defined as Day 1. Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Day 2 at 24, 36 hrs; Day 3 at 48 hrs.

  10. Apparent Total Clearance (CL/F) of Unchanged Edaravone After Oral Administration

    Time frame: The date of dosing is defined as Day 1. Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; Day 2 at 24, 36 hrs; Day 3 at 48 hrs.

  11. Apparent Volume of Distribution During Terminal Phase (Vz/F) of Unchanged Edaravone After Oral Administration

    Time frame: The date of dosing is defined as Day 1. Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; Day 2 at 24, 36 hrs; Day 3 at 48 hrs.

  12. Apparent Volume of Distribution at Steady State (Vss/F) of Unchanged Edaravone After Oral Administration

    Time frame: The date of dosing is defined as Day 1. Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; Day 2 at 24, 36 hrs; Day 3 at 48 hrs.

  13. Cumulative Amount of Drug Excreted in Urine From Time Zero up to 48 Hours (Ae0-48)

    Time frame: Urine samples are collected: Day1 to 6.

  14. Cumulative Percentage of Drug Excreted in Urine From Time Zero up to 48 Hours (Ae0-48)

    Time frame: Urine samples are collected: Day1 to 6.

  15. Renal Clearance (CLr) of Unchanged Edaravone

    Time frame: Urine samples are collected: Day1 to 6.

  16. Bioavailability (F) of Unchanged Edaravone After Oral Administration

    Bioavailability was calculated from ratio of AUC0-inf of unchanged edaravone after oral and intravenous administration.

    Time frame: PO: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 12 hrs; Day 2 at 24 and 36 hrs; Day 3 at 48 hrs. IV: Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75,2, 3, 4, 6, 8, 12 hrs; Day 2 at 24 and 36 hrs; Day 3 at 48hrs.

  17. AUC0-t of Sulfate and Glucuronide Conjugates After Oral and Intravenous Administration

    Time frame: The date of dosing is defined as Day 1. PO: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; IV: Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Both groups: Day 2 at 24, 36 hrs; Day 3 at 48 hrs.

  18. AUC0-inf of Sulfate and Glucuronide Conjugates After Oral and Intravenous Administration

    Time frame: The date of dosing is defined as Day 1. PO: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; IV: Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Both groups: Day 2 at 24, 36 hrs; Day 3 at 48 hrs.

  19. Cmax of Sulfate and Glucuronide Conjugates After Oral and Intravenous Administration

    Time frame: The date of dosing is defined as Day 1. PO: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; IV: Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Both groups: Day 2 at 24, 36 hrs; Day 3 at 48 hrs.

  20. Number of Participants With Adverse Events and Adverse Drug Reactions

    Time frame: Day 1 to 11

07

Results

Posted Jan 18, 2024

Participant flow

Period 1
Participant flow — Period 1
MilestoneEdaravone Oral Suspensione First, Then Edaravone IV FormulationEdaravone IV Formulation First, Then Edaravone Oral Suspension
Started2121
Completed2121
Not completed00
Period 2
Participant flow — Period 2
MilestoneEdaravone Oral Suspensione First, Then Edaravone IV FormulationEdaravone IV Formulation First, Then Edaravone Oral Suspension
Started2121
Completed2121
Not completed00

Outcome measures

PrimaryArea Under the Plasma Concentration Versus Time Curve From Time Zero up to the Last Quantifiable Concentration Time-point (AUC0-t) of Unchanged Edaravone After Oral and Intravenous Administration
Time frame:
The date of dosing is defined as Day 1. PO: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; IV: Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Both groups: Day 2 at 24, 36 hrs; Day 3 at 48 hrs.
Reported as:
Mean · ng·h/mL
Area Under the Plasma Concentration Versus Time Curve From Time Zero up to the Last Quantifiable Concentration Time-point (AUC0-t) of Unchanged Edaravone After Oral and Intravenous Administration
ng·h/mLEdaravone Oral SuspensionEdaravone IV Formulation
Area Under the Plasma Concentration Versus Time Curve From Time Zero up to the Last Quantifiable Concentration Time-point (AUC0-t) of Unchanged Edaravone After Oral and Intravenous Administration1743 ± 5341720 ± 326
Statistical analysis
  • Edaravone Oral Suspension vs Edaravone IV Formulation · Ratio (po/iv): 0.97 · 90% CI 0.91 to 1.04
PrimaryArea Under the Plasma Concentration Versus Time Curve From Time Zero up to Infinity With Extrapolation of the Terminal Phase (AUC0-inf) of Unchanged Edaravone After Oral and Intravenous Administration
Time frame:
The date of dosing is defined as Day 1. PO: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; IV: Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Both groups: Day 2 at 24, 36 hrs; Day 3 at 48 hrs.
Reported as:
Mean · ng·h/mL
Area Under the Plasma Concentration Versus Time Curve From Time Zero up to Infinity With Extrapolation of the Terminal Phase (AUC0-inf) of Unchanged Edaravone After Oral and Intravenous Administration
ng·h/mLEdaravone Oral SuspensionEdaravone IV Formulation
Area Under the Plasma Concentration Versus Time Curve From Time Zero up to Infinity With Extrapolation of the Terminal Phase (AUC0-inf) of Unchanged Edaravone After Oral and Intravenous Administration1762 ± 5401736 ± 331
Statistical analysis
  • Edaravone Oral Suspension vs Edaravone IV Formulation · Ratio (po/iv): 0.98 · 90% CI 0.92 to 1.04
PrimaryMaximum Plasma Concentration (Cmax) of Unchanged Edaravone After Oral and Intravenous Administration
Time frame:
The date of dosing is defined as Day 1. PO: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; IV: Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Both groups: Day 2 at 24, 36 hrs; Day 3 at 48 hrs.
Reported as:
Mean · ng/mL
Maximum Plasma Concentration (Cmax) of Unchanged Edaravone After Oral and Intravenous Administration
ng/mLEdaravone Oral SuspensionEdaravone IV Formulation
Maximum Plasma Concentration (Cmax) of Unchanged Edaravone After Oral and Intravenous Administration1656 ± 733.61253 ± 228.9
Statistical analysis
  • Edaravone Oral Suspension vs Edaravone IV Formulation · Ratio (po/iv): 1.22 · 90% CI 1.09 to 1.36
SecondaryTime to Reach Maximum Plasma Concentration (Tmax)
Time frame:
The date of dosing is defined as Day 1. PO: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; IV: Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Both groups: Day 2 at 24, 36 hrs; Day 3 at 48 hrs.
Reported as:
Median · h
Time to Reach Maximum Plasma Concentration (Tmax)
hEdaravone Oral SuspensionEdaravone IV Formulation
Unchanged edaravone0.50 (0.25 to 0.75)1.00 (0.98 to 1.02)
Sulfate conjugate0.75 (0.50 to 1.00)1.08 (0.98 to 1.25)
Glucuronide Conjugate0.75 (0.25 to 1.00)1.08 (1.00 to 1.27)
SecondaryArea Under the Plasma Concentration Versus Time Curve From Time Zero up to 24 Hours (AUC0-24)
Time frame:
The date of dosing is defined as Day 1. PO: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; Day 2 at 24 hrs ; IV: Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75,2, 3, 4, 6, 8, 12 hrs; Day 2 at 24 hrs.
Reported as:
Mean · ng·h/mL
Area Under the Plasma Concentration Versus Time Curve From Time Zero up to 24 Hours (AUC0-24)
ng·h/mLEdaravone Oral SuspensionEdaravone IV Formulation
Unchanged edaravone1735 ± 5231714 ± 317
Sulfate conjugate19837 ± 518514830 ± 3519
Glucuronide Conjugate3917 ± 7272288 ± 479
SecondaryArea Under the Plasma Concentration Versus Time Curve From Time Zero up to the Last Sampling Time-point (for All Time-points) (AUC0-all)
Time frame:
The date of dosing is defined as Day 1. PO: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; IV: Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Both groups: Day 2 at 24, 36 hrs; Day 3 at 48 hrs.
Reported as:
Mean · ng·h/mL
Area Under the Plasma Concentration Versus Time Curve From Time Zero up to the Last Sampling Time-point (for All Time-points) (AUC0-all)
ng·h/mLEdaravone Oral SuspensionEdaravone IV Formulation
Unchanged edaravone1752 ± 5321727 ± 323
Sulfate conjugate20035 ± 525215025 ± 3575
Glucuronide Conjugate3927 ± 7302297 ± 481
SecondaryTerminal Elimination Half-life (t1/2)
Time frame:
The date of dosing is defined as Day 1. PO: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; IV: Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Both groups: Day 2 at 24, 36 hrs; Day 3 at 48 hrs.
Reported as:
Mean · h
Terminal Elimination Half-life (t1/2)
hEdaravone Oral SuspensionEdaravone IV Formulation
Unchanged edaravone9.75 ± 8.478.82 ± 8.33
Sulfate conjugate5.77 ± 1.857.58 ± 2.39
Glucuronide Conjugate3.75 ± 0.553.69 ± 0.48
SecondaryElimination Rate Constant From the Central Compartment (Kel)
Time frame:
The date of dosing is defined as Day 1. PO: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; IV: Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Both groups: Day 2 at 24, 36 hrs; Day 3 at 48 hrs.
Reported as:
Mean · 1/h
Elimination Rate Constant From the Central Compartment (Kel)
1/hEdaravone Oral SuspensionEdaravone IV Formulation
Unchanged edaravone0.1194 ± 0.08760.1156 ± 0.0563
Sulfate conjugate0.1295 ± 0.03180.1010 ± 0.0324
Glucuronide Conjugate0.1909 ± 0.04170.1924 ± 0.038
SecondaryMean Residence Time From Time Zero up to Infinity With Extrapolation of the Terminal Phase (MRT0-inf) of Unchanged Edaravone
Time frame:
The date of dosing is defined as Day 1. PO: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; IV: Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Both groups: Day 2 at 24, 36 hrs; Day 3 at 48 hrs.
Reported as:
Mean · h
Mean Residence Time From Time Zero up to Infinity With Extrapolation of the Terminal Phase (MRT0-inf) of Unchanged Edaravone
hEdaravone Oral SuspensionEdaravone IV Formulation
Mean Residence Time From Time Zero up to Infinity With Extrapolation of the Terminal Phase (MRT0-inf) of Unchanged Edaravone2.495 ± 0.9032.333 ± 0.826
SecondaryTotal Clearance (CL) of Unchanged Edaravone After Intravenous Administration
Time frame:
The date of dosing is defined as Day 1. Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Day 2 at 24, 36 hrs; Day 3 at 48 hrs.
Reported as:
Mean · L/h
Total Clearance (CL) of Unchanged Edaravone After Intravenous Administration
L/hEdaravone IV Formulation
Total Clearance (CL) of Unchanged Edaravone After Intravenous Administration35.9 ± 7.5
SecondaryVolume of Distribution During Terminal Phase (Vz) of Unchanged Edaravone After Intravenous Administration
Time frame:
The date of dosing is defined as Day 1. Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Day 2 at 24, 36 hrs; Day 3 at 48 hrs.
Reported as:
Mean · L
Volume of Distribution During Terminal Phase (Vz) of Unchanged Edaravone After Intravenous Administration
LEdaravone IV Formulation
Volume of Distribution During Terminal Phase (Vz) of Unchanged Edaravone After Intravenous Administration418 ± 321
SecondaryVolume of Distribution at Steady State (Vss) of Unchanged Edaravone After Intravenous Administration
Time frame:
The date of dosing is defined as Day 1. Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Day 2 at 24, 36 hrs; Day 3 at 48 hrs.
Reported as:
Mean · L
Volume of Distribution at Steady State (Vss) of Unchanged Edaravone After Intravenous Administration
LEdaravone IV Formulation
Volume of Distribution at Steady State (Vss) of Unchanged Edaravone After Intravenous Administration63.1 ± 22.0
SecondaryApparent Total Clearance (CL/F) of Unchanged Edaravone After Oral Administration
Time frame:
The date of dosing is defined as Day 1. Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; Day 2 at 24, 36 hrs; Day 3 at 48 hrs.
Reported as:
Mean · L/h
Apparent Total Clearance (CL/F) of Unchanged Edaravone After Oral Administration
L/hEdaravone IV Formulation
Apparent Total Clearance (CL/F) of Unchanged Edaravone After Oral Administration67.9 ± 30.1
SecondaryApparent Volume of Distribution During Terminal Phase (Vz/F) of Unchanged Edaravone After Oral Administration
Time frame:
The date of dosing is defined as Day 1. Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; Day 2 at 24, 36 hrs; Day 3 at 48 hrs.
Reported as:
Mean · L
Apparent Volume of Distribution During Terminal Phase (Vz/F) of Unchanged Edaravone After Oral Administration
LEdaravone Oral Suspension
Apparent Volume of Distribution During Terminal Phase (Vz/F) of Unchanged Edaravone After Oral Administration826 ± 618
SecondaryApparent Volume of Distribution at Steady State (Vss/F) of Unchanged Edaravone After Oral Administration
Time frame:
The date of dosing is defined as Day 1. Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; Day 2 at 24, 36 hrs; Day 3 at 48 hrs.
Reported as:
Mean · L
Apparent Volume of Distribution at Steady State (Vss/F) of Unchanged Edaravone After Oral Administration
LEdaravone Oral Suspension
Apparent Volume of Distribution at Steady State (Vss/F) of Unchanged Edaravone After Oral Administration164.0 ± 78.9
SecondaryCumulative Amount of Drug Excreted in Urine From Time Zero up to 48 Hours (Ae0-48)
Time frame:
Urine samples are collected: Day1 to 6.
Reported as:
Mean · mg
Cumulative Amount of Drug Excreted in Urine From Time Zero up to 48 Hours (Ae0-48)
mgEdaravone Oral SuspensionEdaravone IV Formulation
Unchanged edaravone0.66 ± 0.210.52 ± 0.15
Sulfate conjugate10.04 ± 8.677.06 ± 6.43
Glucuronide Conjugate125.9 ± 19.094.3 ± 13.7
SecondaryCumulative Percentage of Drug Excreted in Urine From Time Zero up to 48 Hours (Ae0-48)
Time frame:
Urine samples are collected: Day1 to 6.
Reported as:
Mean · percentage of dose
Cumulative Percentage of Drug Excreted in Urine From Time Zero up to 48 Hours (Ae0-48)
percentage of doseEdaravone Oral SuspensionEdaravone IV Formulation
Unchanged edaravone0.629 ± 0.1990.869 ± 0.252
Sulfate conjugate6.58 ± 5.688.09 ± 7.37
Glucuronide Conjugate59.8 ± 9.078.4 ± 11.4
SecondaryRenal Clearance (CLr) of Unchanged Edaravone
Time frame:
Urine samples are collected: Day1 to 6.
Reported as:
Mean · L/h
Renal Clearance (CLr) of Unchanged Edaravone
L/hEdaravone Oral SuspensionEdaravone IV Formulation
Renal Clearance (CLr) of Unchanged Edaravone0.424 ± 0.2270.311 ± 0.114
SecondaryBioavailability (F) of Unchanged Edaravone After Oral Administration

Bioavailability was calculated from ratio of AUC0-inf of unchanged edaravone after oral and intravenous administration.

Time frame:
PO: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 12 hrs; Day 2 at 24 and 36 hrs; Day 3 at 48 hrs. IV: Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75,2, 3, 4, 6, 8, 12 hrs; Day 2 at 24 and 36 hrs; Day 3 at 48hrs.
Reported as:
Mean · percentage bioavailability
Bioavailability (F) of Unchanged Edaravone After Oral Administration
percentage bioavailabilityEdaravone Oral Suspension
Bioavailability (F) of Unchanged Edaravone After Oral Administration57.3 ± 12.6
SecondaryAUC0-t of Sulfate and Glucuronide Conjugates After Oral and Intravenous Administration
Time frame:
The date of dosing is defined as Day 1. PO: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; IV: Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Both groups: Day 2 at 24, 36 hrs; Day 3 at 48 hrs.
Reported as:
Mean · ng·h/mL
AUC0-t of Sulfate and Glucuronide Conjugates After Oral and Intravenous Administration
ng·h/mLEdaravone Oral SuspensionEdaravone IV Formulation
Sulfate conjugate20031 ± 525515024 ± 3576
Glucuronide Conjugate3914 ± 7302285 ± 481
SecondaryAUC0-inf of Sulfate and Glucuronide Conjugates After Oral and Intravenous Administration
Time frame:
The date of dosing is defined as Day 1. PO: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; IV: Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Both groups: Day 2 at 24, 36 hrs; Day 3 at 48 hrs.
Reported as:
Mean · ng·h/mL
AUC0-inf of Sulfate and Glucuronide Conjugates After Oral and Intravenous Administration
ng·h/mLEdaravone Oral SuspensionEdaravone IV Formulation
Sulfate conjugate20055 ± 525615055 ± 3579
Glucuronide conjugate3924 ± 7312295 ± 482
SecondaryCmax of Sulfate and Glucuronide Conjugates After Oral and Intravenous Administration
Time frame:
The date of dosing is defined as Day 1. PO: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; IV: Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Both groups: Day 2 at 24, 36 hrs; Day 3 at 48 hrs.
Reported as:
Mean · ng/mL
Cmax of Sulfate and Glucuronide Conjugates After Oral and Intravenous Administration
ng/mLEdaravone Oral SuspensionEdaravone IV Formulation
Sulfate conjugate7291 ± 18984843 ± 817.8
Glucuronide conjugate2237 ± 3881012 ± 235.7
SecondaryNumber of Participants With Adverse Events and Adverse Drug Reactions
Time frame:
Day 1 to 11
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events and Adverse Drug Reactions
ParticipantsEdaravone Oral SuspensionEdaravone IV Formulation
Number of Participants with Adverse events11
Number of Participants with adverse drug reactions00

Adverse events

Collected over Day 1 to Day 11. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Edaravone Oral Suspension0/42 (0%)0/42 (0%)1/42 (2.4%)
Edaravone IV Formulation0/42 (0%)0/42 (0%)1/42 (2.4%)
Most frequent other events
Most frequent other events
EventEdaravone Oral SuspensionEdaravone IV Formulation
ConstipationGastrointestinal disorders1/420/42
Aspartate aminotransferase increasedInvestigations0/421/42

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Edaravone Oral Suspensione First, Then Edaravone IV FormulationEdaravone IV Formulation First, Then Edaravone Oral SuspensionTotal
<=18 years000
Between 18 and 65 years212142
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Edaravone Oral Suspensione First, Then Edaravone IV FormulationEdaravone IV Formulation First, Then Edaravone Oral SuspensionTotal
Female7714
Male141428
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Edaravone Oral Suspensione First, Then Edaravone IV FormulationEdaravone IV Formulation First, Then Edaravone Oral SuspensionTotal
American Indian or Alaska Native000
Asian212142
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

1 site
  • Investigational site
    Tokyo, Japan
09

References and documents

Publications

  • Shimizu H, Nishimura Y, Shiide Y, Yoshida K, Hirai M, Matsuda M, Nakamaru Y, Kato Y, Kondo K. Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects. Clin Pharmacol Drug Dev. 2021 Oct;10(10):1188-1197. doi: 10.1002/cpdd.952. Epub 2021 May 6. PubMed 33955162 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in Apr 2019, 0 months.

Results were first posted in Jan 2024, 4 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2020
First posted
Jul 30, 2020
StartActual
Mar 22, 2019
Primary completionActual
Apr 21, 2019
CompletionActual
May 9, 2019
Results first posted
Jan 18, 2024
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04493281
Lead sponsor
Shionogi
Responsible party
Sponsor
First posted
Jul 30, 2020
Start date
Mar 22, 2019
Primary completion
Apr 21, 2019
Completion
May 9, 2019
Results posted
Jan 18, 2024
Last update
Jul 15, 2026

Study contacts

Shionogi Clinical Trials Administrator Clinical Support Help Line
study director · Shionogi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Edaravone

Start the discussion